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Polyunsaturated fatty acids omega-3 (n-3 PUFA), such as docosahexaenoic acid (DHA), have 
been shown to prevent, and partially reverse, neurotoxin-induced nigrostriatal denervation in 
animal models of Parkinson’s disease (PD). However, the accumulation of α-synuclein (αSyn) in 
cerebral tissues is equally important to the pathophysiology. To determine whether DHA intake 
improves various aspects related to synucleinopathy, ninety male mice overexpressing human 
αSyn under the Thy-1 promoter (Thy1-αSyn) were fed one of three diets (specially formulated 
control, low n-3 PUFA or high DHA) and compared to non-transgenic C57/BL6 littermate mice 
exposed to a control diet. Thy1-αSyn mice displayed impaired motor skills, lower dopaminergic 
neuronal counts within the substantia nigra (-13%) in parallel to decreased levels of the striatal 
dopamine transporter (DAT) (-24%), as well as reduced synaptic proteins PSD-95 (-51%) and 
synaptophysin (-80%) in the cerebral cortex compared to C57/BL6 mice. However, no significant 
difference in dopamine concentrations was observed by HPLC analysis between Thy1-aSyn and 
non-transgenic C57BL/6 littermates under the control diet. The most striking finding was a 
favorable effect of DHA on the survival/longevity of Thy1-αSyn mice (+51% survival at 12 
months of age). However, dietary DHA supplementation did not have a significant effect on other 
parameters examined in this study, despite increased striatal dopamine concentrations. While 
human αSyn monomers and oligomers were detected in the cortex of Thy1-αSyn mice, the 
effects of the diets were limited to a small increase of 42 kDa oligomers in insoluble protein 
fractions upon n-3 PUFA deprivation. Overall, our data indicate that a diet rich in n-3 PUFA has 
a beneficial effect on the longevity of a murine model of α-synucleinopathy without a major 
impact on the dopamine system and motor impairments, nor αSyn levels.  
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A number of epidemiological and preclinical studies suggest that consumption of diets enriched 
in n-3 polyunsaturated fatty acids (PUFA) may decrease the risk of developing 
neurodegenerative diseases such as Parkinson’s disease (PD) (Bousquet et al., 2011a; 
Bousquet et al., 2011b; Calon and Cicchetti, 2009; Coulombe et al., 2016; de Lau et al., 2005; 
Dyall, 2015). Most evidence of neuroprotection by n-3 PUFA has been collected in animal 
models of PD supplemented with docosahexaenoic acid (DHA; 22:6 n-3, or cervonic acid) and/or 
eicosapentaenoic acid (EPA, 20:5 n-3) (Bousquet et al., 2011a; Bousquet et al., 2008; Dyall, 
2015; Seidl et al., 2014). Our group has previously shown that a formulation containing DHA and 
EPA (4:1 ratio) prevents nigral toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) - a 
compound classically used to reproduce dopaminergic-associated features of PD in mice 
(Bousquet et al., 2011a; Bousquet et al., 2009; Bousquet et al., 2011b; Bousquet et al., 2008). 
This is supported by additional reports in the MPTP-probenecid model exposed to EPA 
(Luchtman et al., 2012). More recently, we have shown that DHA induces a partial recovery of 
the dopaminergic system following a 6-hydroxydopamine lesion (Coulombe et al., 2016), 
suggesting that DHA not only has a neuroprotective effect but can also act as a neurorestorative 
compound. The mechanisms underlying the beneficial properties of DHA include neurotrophic 
factor secretion (Bousquet et al., 2009), dampening of the inflammatory cascades (Calder, 
2013), prevention of oxidative damage (Cardoso et al., 2014), and stimulation of cell survival 
pathways (Akbar et al., 2005), all processes potentially involved in the cell death characteristic of 
PD. Beside possible effects on mood-related symptoms (da Silva et al., 2008), no clinical 
intervention trial has confirmed a neuroprotective effect of n-3 PUFA in PD. 
 
In addition to the prominent dopaminergic cell loss observed in PD, pathological hallmarks of the 
disease include abnormal levels and/or phosphorylation of the protein α-synuclein (αSyn), which 
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is now the target of various therapeutic developments (Dehay et al., 2015; Spillantini and 
Goedert, 2016; Vaikath et al., 2015). Indeed, genetic data suggest that accumulation of αSyn 
deposits may play a causal role in PD. For example, increased αSyn levels generated by gene 
duplication or triplication lead to familial forms of PD (Lee and Trojanowski, 2006; Ross et al., 
2008; Singleton et al., 2004). Cellular αSyn levels accumulate with aging prior to the formation of 
inclusions, suggesting that blocking age-related accumulation of non-aggregated αSyn may alter 
the progression of PD (Chu and Kordower, 2007). In sporadic forms of PD, αSyn accumulation 
and deposition into Lewy bodies is a neuropathological hallmark of the disease, essential for its 
definitive diagnosis (Dickson et al., 2009). Equally important, αSyn has been shown to trigger 
neuroinflammation, as well as mitochondrial dysfunction and oxidative stress, which in turn may 
contribute to neuronal degeneration (Dehay et al., 2015). Conversely, there is a significant 
amount of literature supporting the hypothesis that n-3 PUFA corrects neuroinflammation and 
oxidative stress (Bousquet et al., 2011a; Calon et al., 2004; Delattre et al., 2010; Lalancette-
Hébert et al., 2011; Mori et al., 2017; Trepanier et al., 2016). Furthermore, a meta-analysis has 
established that intake of n-3 PUFA is associated with a lower PD risk (Kamel et al., 2014). 
However, previous reports also suggest that DHA enhances αSyn oligomerization (Yakunin et 
al., 2012). These studies combined provide compelling arguments that DHA or oxidized 
metabolites interact specifically with αSyn, thereby influencing its 3D conformation, its oxidant 
scavenger activity and possibly its propensity to form aggregates and Lewy bodies (Assayag et 
al., 2007; De Franceschi et al., 2017; 2009; Ruiperez et al., 2010; Sharon et al., 2003). 
Therefore, it is critical to determine whether dietary PUFA improve or exacerbate cerebral 
synucleinopathies in vivo.   
 
While the MPTP mouse model of PD generates sufficient dopaminergic cell loss to test the 
neuroprotective capacities of various compounds, it fails to mimic other aspects of the disease 
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such as the accumulation of αSyn (Bezard and Przedborski, 2011; Bezard et al., 2013). To 
palliate to this important shortcoming of toxin-induced models of PD, different lines of mice 
overexpressing αSyn have been generated (Chesselet et al., 2012; Masliah, 2000). Among 
these transgenic germlines, the mouse overexpressing wild-type human αSyn under the neuron-
specific Thy1 promoter (Thy1-αSyn) has been extensively characterized (Chesselet et al., 2012; 
Masliah, 2000) and has been shown to display high levels of αSyn and proteinase K-resistant 
inclusions containing αSyn in several brain regions, including the substantia nigra (Chesselet et 
al., 2012; Masliah, 2000). Although frank nigrostriatal cell loss has not been reported (Chesselet 
et al., 2012), Thy1-αSyn mice exhibit robust behavioral deficits under challenging motor tests, 
such as the beam traversal and pole tests, as well as signs of inflammation, mitochondrial 
dysfunction, and a broad range of deficits in non-motor domains affected by PD (Chesselet et 
al., 2012; Fleming et al., 2004). Thus, the Thy1-αSyn model stands as one of the best animal 
models to study α-synucleinopathies associated with PD.  
 
We therefore sought to evaluate the effects of a nutraceutical intervention with DHA in the Thy1-
αSyn mouse to determine whether the diet has a ‘disease-modifying’ effect on synucleinopathy, 
motor deficits and the dopaminergic nigrostriatal system.  
 
2. MATERIALS AND METHODS 
2.1 Animals 
Male Thy1-αSyn mice (n=90) and non-transgenic (C57BL/6 NonTg, n=31) littermates were bred 
in our animal research facility from Thy1.2-αSyn mice (line 61) - obtained from Dr E. Masliah 
(UCSD) (Hashimoto et al., 2003) - on a full C57BL/6 background. Since the transgene is located 
on chromosome X, only males were selected for experimentations, while females were used for 
breeding. Additional male C57BL/6 were ordered from Jackson Laboratories as breeders. Mice 
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were housed in ventilated cages (between two to five animals per cage), on a 12:12h dark:light 
cycle in a vivarium dedicated to mice. All animals had free access to water and fed with their 
respective diets (formulated control, no DHA or enriched in DHA, see details in sections below). 
All experiments were performed in accordance with the Canadian Guide for the Care and Use of 
Laboratory animals and all procedures were approved by the animal research committee of the 
Centre de recherche du CHU de Québec. 
 
2.2 Diets 
Thy1-αSyn mice were either fed with a control (n=31), low n-3 PUFA (n=30) or a DHA-enriched 
diet (n=30) for ten months, beginning at 2 months of age until their sacrifice at twelve months. 
They were compared with C57BL/6 non-transgenic littermates fed the control diet (n=31). DHA 
was obtained in a microencapsulated formulation (1:25 ratio of EPA to DHA) to avoid oxidation 
(DSM Nutritional Products) and the pelleted chow was generated by Research Diets Inc. (NJ, 
USA). We used only purified diet formulations that were standardized to ensure consistency and 
eliminate batch-to-batch variation. Both diets were isocaloric and contained similar 
concentrations of macronutrients, vitamins and minerals. The dose of DHA was approximately 
~0.8 g/kg/daily per animal. Detailed descriptions of diet contents are provided in Table 1. 
 
2.3 Behavioral measures   
Behavioral testing began when mice reached four months of age - two months after the animals 
were put on their specific diets - and was repeated at eight and twelve months. For the 
behavioral measures, the number of animals used for each testing session may differ due to 
exclusion based on each test criteria, death of the animal or unavailability of the experimenters 
at preset timepoints. All tests were performed in the morning and on consecutive days (a single 
test per day), by experimenters blind to treatment conditions. The animals were evaluated for 
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spontaneous activity where they were placed in a cylinder of ten centimeters in diameter for a 3-
minute observational period. The number of contacts made by each paw against the glass walls 
were counted, as is done with unilateral 6-hydroxydopamine lesioned animals, to investigate 
limb movement asymmetry due to dopamine impairments (Glajch et al., 2012).  
 
The beam test was adapted from previous beam-walking tests (Drucker-Colín and García-
Hernández, 1991). The beam was built from Plexiglas and consisted of four sections of 25 cm 
each for a total length of 1 m. Each section had a different width, starting from 3.5 cm and 
decreasing by 0.5 cm in each section, reaching a width of 1.5 cm on the last section of the 
beam. Animals were trained to cross the entire length of the beam for 2 days at a frequency of 5 
trials per day. On the third day, the test was performed and filmed. The videotapes were 
subsequently analyzed for the number of steps made by each animal, the time to cross the 
beam for the five trials as well as the total number of errors made (Brooks and Dunnett, 2009; 
Fleming et al., 2004). An "error" is considered a step that the mouse missed (i.e. placing its paw 
in imbalance) on the beam during crossing. 
 
The pole test was performed to evaluate motor coordination (Drouin-Ouellet et al., 2012). Briefly, 
animals were placed head-up on top of a vertical 50-cm-high wooden pole with a diameter of 1 
cm. Once placed on the pole, the time for the animal to orient itself downwards and the time to 
descend the entire pole length were calculated. A maximum of 30 seconds was allowed for the 
animal to both turn downward and climb down the pole. A 30-second score was attributed in 
case of a fall (Fleming et al., 2004). The animals received 2 days of training and were tested at a 




For the hanging wire test (cable test), each animal was allowed to grab the wire by its forelimbs 
only. The time the mouse remained suspended was measured (60 seconds maximum). The test 
was performed 3 times, with a rest period of 30 seconds between each trial (Arsenault et al., 
2011).  
 
Mice were further tested using the open field to quantify general locomotion (Coulombe et al., 
2016). The total distance travelled and speed of movements were recorded during a period of 60 
minutes. 
 
2.4 Tissue preparation  
Animals were sacrificed at twelve months of age by intracardiac perfusion of phosphate buffer 
saline (PBS) containing inhibitors of proteases and phosphatases (Sigma-Aldrich) performed 
under deep anesthesia using ketamine and xylazine mixture (100 mg/kg and 10 mg/kg, 
respectively). Brains were collected and hemispheres separated. One side was snap frozen and 
stored at -80°C for cryostat sectioning into coronal sections of 20 μm in thickness, to dissect 
frozen samples from the striatum for Western blot and high-performance liquid chromatography 
(HPLC) analyses. Additional 12-μm thick sections from the same frozen hemisphere were 
prepared for in situ hybridization and autoradiography experiments. The other hemisphere was 
post-fixed in 4% paraformaldehyde (PFA) for 48 hours, transferred to 20% sucrose in 0.1 M PBS 
(pH 7.4) for cryoprotection and ultimately sliced at 25 μm using a freezing microtome (Leica 
Microsystems Inc., ON, Canada) (Bousquet et al., 2009; Bousquet et al., 2008).  
 
2.5 Lipid extraction and gas chromatography 
Brain fatty acid profiles were measured using approximately 10 mg of prefrontal cortex. Total 
lipids were extracted with 2:1 chloroform-methanol, saponified and transmethylated in a solution 
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of 14% methanolic boron trifluoride. Fatty acid profiles were determined by gas chromatography 
equipped with a flame ionization detector (model 6890; Agilent, Palo Alto, CA, USA) and a 50-m 
BPX-70 fused capillary column (SGE, Melbourne, Australia; 0.25 mm inner diameter, 0.25 µm 
film thickness) (Plourde et al., 2009). 
 
2.6 HPLC  
Dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were 
quantified by HPLC using electrochemical detection, as previously described (Bousquet et al., 
2008). The anterior striatum between bregma levels 1.18 and 0.02 mm) (Paxinos and Franklin, 
2008) was dissected and homogenized with 180 µl perchloric acid (0.1 N). A volume of 60 µl of 
supernatant was directly injected with a 717 plus autosampler automatic injector, driven by a 
1525 binary pump, separated with an Atlantis dC18 column, and measured with a 2465 
electrochemical detector equipped with a glassy carbon electrode (Waters Limited, Qc, Canada) 
linked to a chart recorder. Electrochemical potential was set to 5 nA. The mobile phase was 
composed of 8% methanol, 0.4 mM EDTA, 2 mM NaCl, 0.9 mM octanic sulfonic acid, 55 mM 
NaH2PO4 and pH was adjusted at 2.9. The mobile phase was delivered at a flow rate of 1.2 
ml/minute with a mean pressure of 3369 psi. HPLC data were normalized to protein 
concentrations, as determined with a bicinchoninic acid protein assay kit using BSA as standard 
(Pierce, Rockford, IL) and according to the manufacturer's protocol. 
 
2.7 Cortical protein levels and Western blot analyses  
Homogenization of samples was performed in 8 volumes of lysis buffer (150 nM NaCl, 10 nM 
NaH2PO4, 1% v/v Triton X-100, 0.5% SDS, and 0.5% sodium deoxycholate) with a mix of 
protease (Roche, ON, Canada) and phosphatase inhibitors (1 mM tetrasodium pyrophosphate 
and 50 mM sodium fluoride). The samples were sonicated (3 x 10-s pulse) and centrifuged for 
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20 minutes at 100 000 g, 4˚C. The supernatant was collected and frozen at -80˚C. The 
quantification of protein concentration was performed using the bicinchoninic acid protein assay 
kit (Thermo Fisher Scientifc). Twelve µg of proteins were heated with Laemmli loading buffer for 
5 minutes and separated by electrophoresis on an 8% SDS-polyacrylamide gel. Proteins were 
then transferred onto 0.45 μm Immobilon PVDF membranes (Millipore ON, Canada) and 
blocked with 5% skimmed milk, and 1% BSA in PBS - 0.05% Tween for 1 hour. The membranes 
were immunoblotted with the following primary antibodies: rabbit aSyn MJFR1 (Abcam; 
1:1,000), mouse anti-CP13 (gift from Dr. Peter Davies, 1:5000), mouse anti-drebrin (Progen; 
1:500), rabbit anti-NeuN (Abcam, ERP12763, 1:5000), mouse anti-postsynaptic density protein 
95 (PSD95, Neuromab, CA, Neuromab; 1:5000), rabbit anti-septin (Novus biological; 1:20,000), 
mouse anti-synaptophysin (Millipore; 1:10 000), rabbit synaptosomal-associate protein 25 
(SNAP25 Covance; 1:20,000), rabbit anti-Tau C-Terminal (Tau C, Dako; 1:20,000), rabbit anti-
tyrosine hydroxylase (TH, Pel-Freez, AR, USA, 1:5000), mouse anti-VGLUT1 (Neuromab, 
1:4000) and a loading control mouse anti-actin (ABM; 1:10,000). After washing the membranes 
in PBS-Tween, they were incubated with the appropriate HRP-coupled anti-mouse or anti-rabbit 
secondary antibodies (Jackson Immunoresearch, PA, USA) followed by detection with 
chemiluminescence reagent (Luminata, Millipore) which was measured with myECL Imager 
(Thermo Fisher Scientific Inc.). Immunoblot band intensity was quantified with Carestream 
Molecular Imaging Software (Molecular Imaging Software version 4.0.5f7, Carestream Health, 
NY, USA). 
 
2.8 Autoradiography  
Striatal dopamine transporter (DAT) specific binding (Bregma level -0.46 mm) was evaluated 
using 125I-RTI-121 [3β-(4-125I-iodophenyl) tropane-2β-carboxylic acid isopropyl ester] (NEN-
DuPont, MA, USA; 2200 Ci/mmol) binding according to previously published procedures 
Coulombe	et	al.,	2017		
	 11	
(Bousquet et al., 2008; Calon et al., 2001). Sections were preincubated at room temperature for 
30 minutes in potassium phosphate buffered saline (KPBS: 10.1 mM NaHPO4, 1.8 mM KH2PO4, 
137 mM NaCl, and 2 mM KCl pH 7.4) followed by a 60-minute incubation at room temperature 
with 20 pM 125I-RTI-121. Mazindol (10 nM) was used to evaluate non-specific binding (Novartis, 
Basel, Switzerland). After two 20-minute washes in PBS, sections were briefly (10 seconds) 
rinsed in distilled water (all at 4°C). Finally, the slide-mounted tissue sections were dried 
overnight at room temperature and exposed on Kodak Biomax film (Sigma-Aldrich) for 24 hours.  
 
2.9 Immunohistochemical evaluation of the nigro-striatal dopaminergic system 
PFA-fixed sections from the substantia nigra pars compacta (SNpc) and the striatum described 
above were washed in 0.1 M PBS and subsequently placed in 3% hydrogen peroxide for 30 
minutes at room temperature. Sections were washed in PBS and placed in a blocking solution 
(PBS, 0.1% Triton X-100 (Sigma-Aldrich) containing 5% normal goat serum (NGS; Wisent, Qc, 
Canada) for 30 minutes. The sections were then incubated overnight at 4˚C with a rabbit primary 
antibody anti-TH (PEL-Freez, 1/5000 for SNpc and 1/500 for striatum) in blocking solution. 
Sections were washed three times in PBS, incubated with a secondary biotinylated goat anti-
rabbit IgG (Jackson Immunoresearch) followed with an incubation with an avidin-biotin 
peroxidase complex (ABC; Vector Laboratories, CA, USA) for 1 hour at room temperature. The 
antibody binding was detected by placing the sections in a solution of 0.05% 3,3’-
diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich) and 0.1% of 30% hydrogen peroxide 
in PBS. The reaction was stopped by extensive washes in PBS. Following the DAB staining, 
sections were counterstained with cresyl violet (sigma-Aldrich), dehydrated and coverslipped.   
 
2.10 Quantification of nigral TH-immunoreactive neurons  
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The number of nigral TH+ neurons was determined by stereological counts under bright-field 
illumination, as previously described (Bousquet et al., 2008). Seven sections immunostained for 
TH and selected through the SNpc (AP: levels of −2.70 mm to −3.80 mm) were analyzed using 
the Stereo investigator software (MicroBrightfield) integrated to an E800 Nikon microscope 
(Nikon Canada Inc., ON, Canada) (Gibrat et al., 2009). Two independent investigators, blinded 
to experimental conditions, performed unbiased cell counts. Analyses of immunoreactive profiles 
were restricted to the SNpc and thus excluded the ventral tegmental area.  
 
2.11 Statistical analyses 
Results for each group are presented as the mean ± SEM. For Western blot data, values that 
were within one standard deviation from the background values were excluded. In cases of 
comparable group variances, as established by a Bartlett’s test, statistical analyses were 
performed using one-way analysis of variance (ANOVA) followed by post-hoc (Tukey’s) tests for 
comparisons between groups. To compare diet and genotype as independent categorical 
variables, we performed two-way ANOVA. For comparisons between two groups, a Student’s t-
test was used. Mann-Whitney test was selected in cases where variances were not equivalent. 
These were identified using the ROUT method, based on the analyses of non-linear regression 
and evaluation of the residuals of the robust fit. All statistical analyses were performed using the 
JMP (version 11; SAS Institute Inc., Cary, IL, USA) and Prism 6 (GraphPad Software Inc., La 
Jolla, CA, USA) softwares. A p value of 0.05 was considered statistically significant. 
 
3. RESULTS 
Accumulation of cerebral DHA levels following exposure to a high n-3 PUFA diet  
High dietary intake of n-3 PUFAs over a period of 10 months in mice (from two to twelve months 
of age) selectively increased frontal cortex levels of DHA (Table 2), confirming treatment 
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efficacy. Dietary intake of DHA decreased levels of total n-6 PUFA, arachidonic acid and adrenic 
acid. The n-3 PUFA:n-6 PUFA ratio also increased with the treatment enriched with DHA (Table 
2). The opposite occurred with an increase of total n-6 PUFA and a decrease of DHA observed 
in animals fed the diet that did not contain DHA, along with a lower n-3 PUFA:n-6 PUFA ratio. 
There was no effect of genotypes on fatty acid profiles (Table 2). 
 
Impact of a DHA enriched diet on mice longevity  
We first assessed whether n-3 PUFA-enriched diet intake improved motor behavior of Thy1-
aSyn mice. Motor performance was evaluated at 4, 8 and 12 months (Figure 1). Thy1-aSyn 
mice made more errors when crossing the beam than the non-transgenic mice (Figure 1B). 
Thy1-aSyn mice took longer to perform the pole test than their control counterparts, particularly 
with advancing age (Figure 1C). DHA treatment aggravated this phenotype in Thy1-aSyn mice 
at each time point, particularly at 4 months of age (Figure 1C). Muscle tone was not modified by 
the diets (hanging wire test). At 4 and 8 months, non-transgenic mice remained suspended to 
the wire for a longer period of time than Thy1-aSyn mice (Figure 1D). The transgene 
significantly decreased the motor fluency of the mice at the three ages evaluated when the 
spontaneous activity test was performed (Figure 1E). In general, Thy1-aSyn mice traveled 
greater distances than non-transgenic mice (Figure 1F). Thy1-aSyn mice on the control diet 
evolved towards reduced hyperactivity at 12 months, consistent with previous observations (Lam 
et al., 2011). The high-DHA diet significantly prevented this decline, although a similar non-
significant trend was also seen with animals on the low n-3 PUFA diet (Figure 1F). Remarkably, 
DHA treatment prolonged the survival of Thy1-aSyn mice (Figure 1G). More than 33% of the 
Thy1-aSyn mice not supplemented with DHA died before reaching 6 months of age, compared 
to 6% for DHA-fed Thy1-aSyn mice. The survival medians for each group were 12, 9, 6 and 12 
months for non-transgenic littermates, Thy1-aSyn on control diet, low n-3 PUFA diet (no DHA) 
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or high-DHA diets, respectively (Figure 1G), indicating that the majority of DHA-treated Thy1-
aSyn mice lived until the fixed sacrifice time. In sum, despite the absence of consistent 
behavioral effects, DHA intake clearly improved the survival of Thy1-aSyn mice. 
 
Confirmation of human aSyn in the Thy1-aSyn brain  
Human aSyn was detected only in brain homogenates derived from Thy1-aSyn and not from 
control C57BL/6 mice, using a rabbit antibody raised against human aSyn (MJFR1) (Figure 2). 
Both soluble (Figure 2A) and insoluble (Figure 2B) protein fractions were quantified by Western 
blot and confirmed the expression of human aSyn in the cortex of Thy1-aSyn mice. The different 
forms of oligomers were identified depending on the band heights on the Western blots (Figure 
2). No significant effect of dietary treatment on the levels of human aSyn was observed, aside 
from higher 42-kDa insoluble oligomer in Thy1-aSyn mice under the DHA deprived diet 
compared to controls or to those supplemented with DHA (Figure 2B). This change in the aSyn-
positive band migrating at 42-kDa should be interpreted with caution, as its levels were very low. 
 
Impact of dietary treatments on the nigro-striatal system 
Three components of the nigro-striatal dopaminergic system were studied: striatal DAT 
terminals, levels of dopamine and metabolites as well as TH-immunoreactivity in the SNpc. No 
significant difference was observed between dietary groups in DAT (Figure 3A,B) nor TH 
analyses in Thy1-aSyn mice (Figure 3C,D). Interestingly, lower SNpc TH signal and DAT levels 
were detected in Thy1-aSyn mice compared to the C57BL/6 mice (both under the control diet) 
when a planned comparison t-test was performed. A two-way ANOVA also revealed a significant 
effect of the Thy1-aSyn genotype on lowering nigral TH immunostaining and DAT levels, but no 
effect of the dietary treatment. Western blot analyses did not reveal a difference in striatal TH 
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levels between genotypes (data not shown). No significant difference in dopamine 
concentrations was detected by HPLC analysis between Thy1-aSyn and non-transgenic 
C57BL/6 littermates under the control diet. However, an increase of striatal dopamine levels was 
observed in Thy1-aSyn mice fed with enriched DHA diet comparatively to other groups (Figure 
3E). Dopamine metabolites did not show any significant difference between groups (Figure 3F 
and G), and only lower DOPAC/DA ratio reached statistical significance in DHA-treated Thy1-
aSyn mice (Figure 3H-I) 
 
 
Changes in synaptic proteins with mice genotypes  
Western blot analysis showed altered synaptic protein levels between genotypes (Figure 4). A 
decrease of synaptophysin, PSD95, VChAT and NeuN was observed in the cerebral cortex for 
all Thy1-aSyn groups regardless of the dietary intake (Figure 4A,D,G,H). Unexpectedly, 
enriched DHA diet also brought a decrease of SNAP25 in transgenic mice (Figure 4B). 
However, drebrin , NeuN and septin concentrations remained unchanged (Figure 4C,E, F). 
 
4. DISCUSSION 
The goal of this study was to extend our prior data demonstrating the beneficial effects of n-3 
PUFA enriched diets in toxin-based animal models of PD to a mouse model of brain 
synucleinopathy. We therefore evaluated the effects of a nutraceutical intervention with DHA in 
the Thy1-αSyn mouse model of PD. Our results demonstrate 1) a significant impairments in 
motor behavior and lower survival rates in a large cohort of Thy1-aSyn mice, 2) that brain aSyn 
accumulation in Thy1-aSyn mice is associated with a robust decrease in the key synaptic 
proteins synaptophysin and PSD95, further accompanied by partial deficits in dopaminergic-
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related parameters, 3) that dietary DHA has a significant beneficial effect on the longevity of 
mice associated with higher dopamine levels, but with limited effects on behavioral impairment 
and no concomitant significant effect on brain aSyn content or synaptic protein levels. 
 
Consistent with previous studies in rodents, the relative concentrations of fatty acids in the brain 
were profoundly altered by dietary intake of n-3 PUFA (Bourre, 1984; Bousquet et al., 2008; 
Coulombe et al., 2016; Lalancette-Hébert et al., 2011; Salem, 1989). More specifically, the 
increase of DHA measured in the prefrontal cortex confirmed the efficacy of the dietary 
treatment to impact brain fatty acid content. However, DHA accumulation in cerebral tissues was 
not clearly translated into detectable effects on motor impairments. On the one hand, DHA-
treated Thy1-aSyn mice performed even more poorly that those on the control diet on the 
hanging wire or the pole tests. On the other hand, the dietary DHA treatment prevented the 
decline in activity observed at 12 months in Thy1-aSyn mice on the control diet. This latter 
observation can be interpreted as a slower progression towards parkinsonism (Lam et al., 2011). 
This should be taken with caution, however, as a similar non-significant trend was observed in 
animals on the low n-3 PUFA diet. The absence of clear motor improvement following DHA 
intake and the resulting dopamine increase is consistent with previous observations that the 
motor impairments observed in the Thy1-aSyn mice are not directly dependent on dopaminergic 
defects (Fleming, 2006; Richter et al., 2014).  
 
A particularly striking observation was that the DHA treatment enhanced survival of the Thy1-
aSyn mouse model of synucleinopathy. The 50% mortality rate observed in Thy1-aSyn mice fed 
the control or DHA-deprived diets was more important than in previous reports, where rising 
mortality was observed only after 14 months of age (Chesselet et al., 2012; Lam et al., 2011). It 
should be noted that we used Thy1-aSyn mice on a fully backcrossed C57Bl/6 background, 
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while most publications use the hybrid C57BL/6-DBA/2 background (Chesselet et al., 2012; Lam 
et al., 2011; Magen et al., 2015), which may have contributed to the higher and earlier mortality 
rate observed here. Although we did not determine the exact causes of mortality, the protective 
effect of the DHA diet may relate to its multiple beneficial effects on different organs, aside from 
the brain, during aging (Trepanier et al., 2016). 
 
As expected, we further confirmed the expression of human aSyn in the cortex of Thy1-aSyn 
mice in the form of monomers, as well as various soluble and insoluble oligomers of 42, 110 and 
260 kDa in size. Dietary treatment had only a minimal effect on cortical levels of human aSyn 
monomers and oligomers with the exception of the 42-kDa insoluble oligomer, which was found 
in higher concentrations in mice fed the low n-3 PUFA diet. It has been proposed that PUFA 
integration in membrane phospholipids alters αSyn associations with cell membrane as well as 
in αSyn oligomerization and aggregation (Sharon et al., 2003b). Indeed, experiments on 
dopaminergic or neuronal cell lines indicate that PUFA regulate oligomerization of monomers 
into higher weight soluble complexes, which could precede Lewy body-like inclusion formation 
(Assayag et al., 2007; Sharon et al., 2003a). More recent findings suggest that dietary 
alterations in brain DHA levels affect αSyn cytopathology in transgenic mice for the PD-causing 
A53T mutation in human αSyn (Yakunin et al., 2012). In addition, there is evidence that these 
associations are involved in the potential physiological function of αSyn, activating mechanisms 
of membrane trafficking and specifically, synaptic vesicle recycling (Emanuele and Chieregatti, 
2015). Nevertheless, the pathogenic role of this specific 42-kDa oligomer present in weak 
concentration in the brain of these mice remains unclear. A similar αSyn band migrating at a 42-
kDa range has been previously observed in the cerebrospinal fluid collected from both PD 
patients and controls (Jakowec, 1998). Although neurotoxicity has been attributed mostly to 
soluble αSyn oligomers, the relative importance of each oligomer, soluble or insoluble, in how 
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they may contribute to the progression to parkinsonism remains unclear (Barrett and 
Greenamyre, 2015; Bartels et al., 2011). Most evidence suggests that the equilibrium between 
monomers and tetramers (58 kDa) is particularly important to the initiation of αSyn misfolding 
and human synucleinopathies (Barrett and Greenamyre, 2015; Bartels et al., 2011). As such, the 
change in 42-kDa oligomer observed in our study may represent a key step affected by DHA in 
the formation of oligomers of larger size or in the process of fibril formation. 
 
Consistent with previous findings, our results evidence only weak decreases in dopaminergic 
markers in the Thy1-aSyn transgenic model, regardless of the dietary treatment. A significant 
decrease of dopaminergic neurons in the SNpc was nonetheless observed at 12 months of age 
in Thy1-aSyn compared to non-transgenic C57BL6, particularly when statistical power was 
increased by pooling all transgenic mice, and ignoring dietary treatment. It is possible that the 
aggregation of human aSyn could potentially need to reach a certain threshold before inducing 
degeneration of the dopaminergic system. Our results are thus consistent with the hypothesis 
that motor dysfunction in the Thy1-aSyn model is not related to dopamine deficits, but to other 
causes such as alterations in corticostriatal synaptic function (Watson et al., 2009), changes in 
gut microbiota and/or central microglia activation (Sampson et al., 2016). Notably, however, we 
observed that DHA treatment stimulates secretion of dopamine in the striatum. This is in 
agreement with reported indication of enhanced dopaminergic drive in animals fed with n-3 
PUFA (Bousquet et al., 2011a; Chalon, 2006; Coulombe et al., 2016; Delattre et al., 2010; Mori 
et al., 2017). The fact that this was not translated into improved behavior remains consistent with 
previous reports that early behavioral deficits in these mice are worsened by either dopaminergic 
agonists (Fleming, 2006) or increased expression of genes associated with the dopaminergic 




The Thy1-aSyn model also showed unexpected reductions in two synaptic proteins in the 
cerebral cortex, namely synaptophysin and PSD95. This observation is consistent with results of 
studies in primary hippocampal neurons showing that exposure to human aSyn induces 
presynaptic toxicity with a decrease in key synaptic proteins, including synaptophysin (Volpicelli-
Daley et al., 2011). This is further in line with neuropathological observations indicating that an 
important proportion of aSyn aggregates are localized in axons in human synucleinopathies, 
leading to the suggestion that aSyn induces synaptic dysfunction before neurodegeneration 
(Lam et al., 2011; Schulz-Schaeffer, 2010; Wu et al., 2010). 
 
Our results reinforce the conclusion that despite a widespread accumulation and aggregation of 
aSyn in the brain, the Thy1-aSyn transgenic model does not present a robust dopaminergic 
degeneration (Chesselet et al., 2012), but rather a loss of synaptic proteins which may be 
relevant to corticostriatal circuit dysfunction observed in early PD (Lam et al., 2011; Rodriguez-
Oroz et al., 2009; Wu et al., 2010). In the present study, DHA dietary treatment did not decrease 
the amount of human aSyn present in the brain of Thy1-aSyn mice, neither did it protect the 
integrity of synaptic proteins. Since no frank dopaminergic loss was observed in this model, it is 
logical that DHA-induced increase in striatal dopamine did not translate into obvious motor 
impairments. Nevertheless, the DHA enriched diet lengthened the survival of Thy1-aSyn mice, 
consistent with a protective action downstream of α-synucleinopathy. Additional investigations 
will be necessary to validate the potential of a DHA-based nutraceutical intervention in PD 
patients but the present data does not suggest that an n-3 PUFA mechanism of action includes 
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Figure 1. Impact of n-3 PUFA on motor behavior and longevity. (A) Time line of 
experimentation. The different behavioral tests revealed a decrease of motor abilities of the 
Thy1-aSyn transgenic mice with age; deficits that were not restored with high DHA intake (B-F). 
However, diets had a significant impact on the percentage of mice that survived up to 12 months 
of age (G). More than 50% of transgenic mice died when fed with low n-3 PUFA diet compared 
to C57BL/6 control mice. In contrast, animals fed a high-DHA had an attrition of only 25% at 12 
months of age (G). Statistical analyses were performed using One-Way ANOVA.  
* P<0.05, ** P<0.01, **** P<0.0001 for C57BL/6 control mice compared to Thy1-aSyn mice on 
control diet;   
## P<0.01, ### P<0.001, #### P<0.0001 for Thy1-aSyn mice on Low n-3 PUFA diet (No DHA) 
compared to C57BL/6 control mice;  
$ P<0.05 $$ P<0.01, $$$ P<0.001, $$$$ P<0.0001 for Thy1-aSyn mice on DHA diet compared 
to C57BL/6 control mice;  
£ P<0.05 ££ P<0.01 £££ P<0.001 for Thy1-aSyn mice on DHA diet compared to Thy1-aSyn 
mice on control diet;  
@ P<0.05 @@ P<0.01 for Thy1-aSyn mice on DHA diet compared to Thy1-aSyn mice on Low 
n-3 PUFA diet (No DHA). Values are expressed as means ± S.E.M. 
 
Figure 2. Impact of n-3 PUFA on human aSyn levels in cerebral tissue. Cortical soluble and 
insoluble fractions of aSyn oligomers were quantified by Western blot. As expected, control mice 
depicted negligible immunoreactivity for the antibody targeting human aSyn (A-B). Additionally, 
diets had a very small impact on aSyn levels, which was limited to an increase of the 42-kDa 
insoluble oligomer in animals fed a low n-3 PUFA diet (no DHA) compared to control (C57 Ctrl) 
or DHA-treated animals (DHA) Thy1-aSyn mice. (B). Statistical analyses were performed using 
One-Way ANOVA. * P<0.05, ** P<0.01, *** P<0,001 **** P<0.0001 compared to background 
levels; # P<0.05 compared to DHA-fed Thy1-aSyn mice. @ P<0.05 for Thy1-aSyn mice on DHA 
diet compared to Thy1-aSyn mice on a low n-3 PUFA diet (No DHA). n.d. : non detectable 
Values are expressed as means ± S.E.M. Values that were within one standard deviation from 
the background values were excluded, which accounts for the different number of animals in 
each group for each analysis. While the example in B is from a single exposure of the 
membrane, relative optical densities were analyzed from different exposure to compare groups, 
thus do not reflect the relative amount of monomers versus each oligomer within samples. 
 
 
Figure 3. Impact of n-3 PUFA on the nigro-striatal system. Thy1-aSyn mice exposed to DHA 
had higher levels of striatal dopamine compared to non-transgenic (C57BL/6, Ctrl) or to Thy1-
aSyn mice fed the n-3 PUFA-depleted diet (no DHA) (A) No significant changes in the ratio 
between metabolites and dopamine were detected (B). Genetic expression of human aSyn led 
to a decrease in 125I-RTI-121 specific binding to DAT (A) and in the number of TH-
immunopositive dopaminergic nigral cells (C) using a 2-way ANOVA. When statistical analyses 
were performed using a One-Way ANOVA, the decrease in both dopaminergic markers was 
significant only in transgenic mice fed with the control diet, compared to C57BL/6 control mice. 
Representative images of 125I-RTI-121 specific binding to DAT and TH immunostaining in the 
mouse substantia nigra (B-D). * P<0.05, ** P<0.01, compared to non-transgenic C57BL/6 control 
mice using a 1-way ANOVA (Tukey’s post-hoc test), # P<0.05 compared to non-transgenic 
C57BL/6 control mice analyses using a 2-way ANOVA, †† P<0.01 versus Low n-PUFA-fed 
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Thy1-aSyn mice (no DHA), using a 1-way ANOVA (Tukey’s post-hoc test). Values are 
expressed as means ± S.E.M. Abbreviations: DOPAC: 3,4-dihydroxyphenylacetic acid, HVA: 
homovanillic acid, DA: dopamine, DAT: dopamine transporter, TH: tyrosine hydroxylase. 
 
Figure 4. Impact of n-3 PUFA on synaptic and neuronal markers. Lower concentrations of 
synaptic proteins synaptophysin, VChAT, PSD95 and NeuN were observed in the cerebral 
cortex of Thy1-aSyn mice compared to non-transgenic C57BL/6 mice, independently of the 
dietary intake of a control (Ctrl), low n-3 PUFA (No DHA) or high-DHA (DHA) diets. (A, D, G, H). 
SNAP25 decreased in the Thy1-aSyn mice fed with DHA enriched diet compared to C57BL/6 
control groups (B). Drebrin and septin-3 remained unchanged (C, E). Actin was used as loading 
control and remained unchanged between each group (F). Western blot bands were cropped 
from the same membrane. Statistical analyses were performed using One-Way ANOVA. * 
P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 compared to C57BL/6 control mice. & P<0.05, && 
P<0.01, &&&, P<0.0001 compared to C57/BL6 control mice using a two-way ANOVA. Values 













 Control Low High 
 n-3 PUFA DHA 
Medium LNA Low LNA Low LNA 
No DHA No DHA High DHA 
Protein (% w/w) 20.3 20.3 20.3 
Carbohydrate (% w/w) 66.0 66.0 66.0 
Fat (% w/w) 5.0 5.0 5.0 












DL-Methionine 3 3 3 
Corn Starch 150 150 150 
Sucrose 500 500 500 
Cellulose, BW200 50 50 50 
Corn Oil 30 25 10 
Safflower Oil 0 25 19 
DHA powder KSF58 0 0 50 
Soybean Oil 10 0 0 
Canola oil 10 0 0 
Fatty acids (g/kg)1 










LNA 1.42 0.28 0.14 
EPA 0 0 0.26 
DHA 0 0 7.20 
Total n-6 PUFA 21.20 30.29 18.42 
Linoleic acid 21.10 30.14 16.65 
Arachidonic acid 0 0 0.06 
n-6:n-3 PUFA ratio 14.82 97.70 2.36 
 
Abbreviations and notes: 
•n-3 and n-6 = n-3 and n-6 polyunsaturated fatty acids (PUFA) 
•DHA: docosahexaenoic acid (22:6n-3) from DHA microencapsulated powder (Martek/DSM) 
•EPA: eicosapentaenoic acid (20:5n-3) 
•LNA: alpha-linolenic acid (18:2 n-3) (from soybean oil) 



















 (No DHA) (No DHA)   
% total fatty acids       
N 8 8 8  8  
C16:0 25.54±0.19 25.37±0.42 25.40±0.15  25.14±0.14  
C18:0 21.69±0.56 20.56±0.80 20.72±0.71  20.37±0.85  
Total SFA 47.22±0.56 45.94±0.92 46.12±0.69  45.51±0.81  
C18:1 n-9 16.42±0.23 16.40±0.43 16.06±0.48 ** 16.50±0.37  
Total MUFA 17.70±0.23 17.88±0.44 20.16±0.56  19.37±0.36  
C18:2 n-6 LA 0.74±0.08 0.73±0.03 0.79±0.04  0.60±0.03  
C20:4 n-6 ARA 11.74±0.27 12.22±0.33 12.37±0.48  10.05±0.23 ††† *** 
C22:4 n-6 DTA 3.05±0.06 3.12±0.11 3.43±0.22  1.89±0.052 †††† **** 
Total n-6 PUFA 16.49±0.99 16.08±0.35 16.59±0.66  12.54±0.27 ††† ** 
C22:6 n-3 DHA 19.54±0.40 20.10±0.61 16.85±0.97 * * 22.58±0.41 †††† * 
Total n-3 PUFA 19.54±0.40 20.10±0.61 16.85±0.97 ** 22.58±0.41 †††† * 
n-3:n-6 ratio 1.21±0.06 1.25±0.04 1.04±0.11  1.80±0.04 †††† **** 
Total PUFA 36.03±1.09 36.18±0.84 33.44±0.91  35.12±0.56  
 
††† P < 0.001, †††† P < 0.0001 versus low n-3 PUFA diet (same genotype) 
* P < 0.05, **P < 0.01, *** < 0.001, **** < 0.0001 versus non-transgenic mice (Ctrl diet) 
 
C16:0; palmitic acid, C18:0; stearic acid, SFA; saturated fatty acid, C18:1 n-9; Oleic acid, MUFA; 
monounsaturated fatty acid, C18:2 n-6 (LA); Linoleic acid, C20:4 n-6 (ARA); Arachidonic acid, 
C22:4 n-6 (DTA); Docosatetraenoic acid, n-6 PUFA; omega-6 polyunsaturated fatty  acids, 
C22:6 n-3 (DHA); Docosahexaenoic acid, n-3 PUFA; omega-3 polyunsaturated fatty acids, n-3; 
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